1,295 research outputs found
"And they fastened his body to the wall of Beth-shan" (1 Sm 31, 10). The problem of a suicide in the Old Testament. This paper addresses a multi-faceted, intriguing issue of suicide in the Bible, especially in Jewish and ancient tradition. The author aims to show all cases of suicide in the Old Testament (Abimelech, Samson, King Saul and his armor-bearer, Ahithophel, Zimri, Ptolemy Macron, Razis), focusing on a theological, linguistic and cultural analysis of selected biblical excerpts. In addition, there are many of suicide prevention in the Bible in which God’s intervention prevented the accomplishment of suicidal behavior (Moses, David, Elijah, Job, Jeremiah, Jonah). Suicide in the Bible occurs for a variety of complicated, ambiguous reasons, including intense personal guilt, sense of hopelessness, human inclination to despair or tremendous personal loss. The Bible nowhere proscribes suicide distinctly, and the question of self-killing in Hebrew Scriptures is a still live dilemma
Alternative HER/PTEN/Akt Pathway Activation in HPV Positive and Negative Penile Carcinomas
No full textThis is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Production and characterization of bacterial cellulose synthesized by Enterobacter chuandaensis strain AEC using Phoenix dactylifera and Musa acuminata
No full textBacterial cellulose (BC) is a biopolymer synthesized extracellularly by certain bacteria through the polymerization of glucose monomers. This study aimed to produce BC using Enterobacter chuandaensis with fruit extracts from Phoenix dactylifera (D) and Musa acuminata (M) as carbon sources. Attenuated Total Reflectance-Fourier Transform Infrared Spectroscopy (ATR-FTIR) showed characteristic cellulose vibrations, while X-ray diffraction (XRD) identified distinct peaks at 15.34°, 19.98°, 22.58°, and 34.6°, confirming the cellulose structure. Whole-genome sequencing of E. chuandaensis identified key genes involved in BC production. The BC produced then exhibited a molecular weight of 1,857,804 g/mol, with yields of 2.8 g/L and 2.5 g/L for treatments D and M, respectively. The crystallinity index of the purified BC was 74.1, and 13C NMR analysis confirmed the dominant cellulose Iα crystalline form. The BC showed high biocompatibility in cytotoxicity assays, with cell viability between 92% and 100%, indicating its potential for use in biomedical applications. This investigation represents the first report of BC production by E. chuandaensis, which promises a new avenue for sustainable and efficient BC synthesis using fruit extracts as carbon sources. © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2024
Phase 2 study of cabazitaxel as second-line treatment in patients with HER2-negative metastatic breast cancer previously treated with taxanes—a Hellenic Cooperative Oncology Group (HeCOG) Trial
No full textBackground: Cabazitaxel is a novel taxane that might be active in breast cancer resistant to first-generation taxanes. Methods: The purpose of the current multicentre phase II trial was to evaluate the activity and safety of cabazitaxel, as second-line treatment, in patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) previously treated with taxanes. The primary endpoint was objective response rate (ORR). Results: Eighty-four patients were enrolled between October 2012 and November 2016. Taxane resistance to previous treatment was detected in 43 cases. The ORR was 22.6% in the intent-to-treat population, 23.3% in taxane-resistant and 20.5% in taxane-non-resistant cases. At a median follow-up of 39.6 months, the median progression-free survival and overall survival were 3.7 months (95% CI 2.2–4.4) and 15.2 months (95% CI 11.3–19.4), respectively. Regarding toxicity, grade 3–4 neutropenia was reported in 22.6% and febrile neutropenia in 6% of the patients, respectively. Two fatal events (one febrile neutropenia and one sepsis) were reported as being related to study treatment. Conclusions: This phase II trial suggests that cabazitaxel is active as second-line treatment in taxane-pretreated patients with HER2-negative MBC, with manageable toxicity. © 2020, The Author(s), under exclusive licence to Cancer Research UK
Hand-foot syndrome with docetaxel: A five-case series
No full text[No abstract available]Abushullaih S, 2002, CANCER INVEST, V20, P3, DOI 10.1081-CNV-120000360; Asgari MM, 1999, J CUTAN PATHOL, V26, P287, DOI 10.1111-j.1600-0560.1999.tb01846.x; BARDIA A, 2006, J CLIN ONCOL, V24, P184; Chu CY, 2000, BRIT J DERMATOL, V142, P808, DOI 10.1046-j.1365-2133.2000.03432.x; Crawford JH, 2002, EUR J HAEMATOL, V69, P315, DOI 10.1034-j.1600-0609.2002.02834.x; D'Agostino G, 2003, BRIT J CANCER, V89, P1180, DOI 10.1038-sj.bjc.6601284; Eich D, 2002, AM J CLIN ONCOL-CANC, V25, P599, DOI 10.1097-00000421-200212000-00015; Feizy Vida, 2003, Dermatol Online J, V9, P14; GORDON KB, 1995, CANCER, V75, P2169, DOI 10.1002-1097-0142(19950415)75:82169::AID-CNCR28207508223.0.CO;2-H; Gressett Sarah M, 2006, J Oncol Pharm Pract, V12, P131, DOI 10.1177-1078155206069242; Hui YF, 2000, PHARMACOTHERAPY, V20, P1221, DOI 10.1592-phco.20.15.1221.34593; Kara IG, 2006, BREAST, V15, P414, DOI 10.1016-j.breast.2005.07.007; Katoh M, 2004, J DERMATOL, V31, P403; Laack E, 2001, ANN ONCOL, V12, P1761, DOI 10.1023-A:1013575816870; Lin E, 2002, ONCOLOGY-NY, V16, P31; LIN EH, 2002, P AM SOC CLIN ONCOL, V21; Lopez AM, 1999, CANCER CHEMOTH PHARM, V44, P303, DOI 10.1007-s002800050981; Mrozek E, 2006, CLIN BREAST CANCER, V7, P141, DOI 10.3816-CBC.2006.n.023; Nagore E, 2000, Am J Clin Dermatol, V1, P225, DOI 10.2165-00128071-200001040-00004; O'Brien MER, 2004, ANN ONCOL, V15, P440, DOI 10.1093-annone-mdh097; PORTAL I, 1994, CANCER CHEMOTH PHARM, V34, P181, DOI 10.1007-BF00685939; Razis E, 2006, CANCER INVEST, V24, P514, DOI 10.1080-07357900600814847; Saif MW, 2006, CLIN COLORECTAL CANC, V6, P219, DOI 10.3816-CCC.2006.n.039; SCHEITHAUER W, 2004, ONCOLOGY WILLISTON P, V18, P1173; SCHEITHAUER W, 2004, ONCOLOGY WILLISTON P, V18, P1181; Scheithauer W, 2004, ONCOLOGY-NY, V18, P1161; Schrijvers D, 2000, BRIT J DERMATOL, V142, P1069, DOI 10.1046-j.1365-2133.2000.03518.x; Scotte F, 2005, J CLIN ONCOL, V23, P4424, DOI 10.1200-JCO.2005.15.651; SILVER FS, 1983, ANN INTERN MED, V98, P675; Vail DM, 1998, CLIN CANCER RES, V4, P1567; VUKELJA SJ, 1993, J NATL CANCER I, V85, P1432, DOI 10.1093-jnci-85.17.1432; Wilkes Gail M, 2005, Clin J Oncol Nurs, V9, P103; ZIMMERMAN GC, 1995, ARCH DERMATOL, V131, P202, DOI 10.1001-archderm.131.2.202; ZIMMERMAN GC, 1994, J NATL CANCER I, V86, P557, DOI 10.1093-jnci-86.7.557; ZUEHLKE RL, 1974, DERMATOLOGICA, V148, P9042
Detection rate for ESR1 mutations is higher in circulating-tumor-cell-derived genomic DNA than in paired plasma cell-free DNA samples as revealed by ddPCR
No full textPlasma cell-free DNA (cfDNA) analysis to track estrogen receptor 1 (ESR1) mutations is highly beneficial for the identification of tumor molecular dynamics and the improvement of personalized treatments for patients with metastatic breast cancer (MBC). Plasma-cfDNA is, up to now, the most frequent liquid biopsy analyte used to evaluate ESR1 mutational status. Circulating tumor cell (CTC) enumeration and molecular characterization analysis provides important clinical information in patients with MBC. In this study, we investigated whether analysis of CTCs and circulating tumor DNA (ctDNA) provide similar or complementary information for the analysis of ESR1 mutations. We analyzed both plasma-cfDNA (n = 90) and paired CTC-derived genomic DNA (gDNA; n = 42) from 90 MBC patients for seven ESR1 mutations. Eight out of 90 (8.9%) plasma-cfDNA samples tested using the ddPLEX Mutation Detection Assay (Bio-Rad, Hercules, CA, USA), were found positive for one ESR1 mutation, whereas 11/42 (26.2%) CTC-derived gDNA samples were found positive for at least one ESR1 mutation. Direct comparison of paired samples (n = 42) revealed that the ESR1 mutation rate was higher in CTC-derived gDNA (11/42, 26.2%) than in plasma-cfDNA (6/42, 14.3%) samples. Our results, using this highly sensitive ddPLEX assay, reveal a higher percentage of mutations in CTC-derived gDNAs than in paired ctDNA in patients with MBC. CTC-derived gDNA analysis should be further evaluated as an important and complementary tool to ctDNA for identifying patients with ESR1 mutations and for guiding individualized therapy. © 2025 The Author(s). Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies
Search for new physics in dijet angular distributions using proton-proton collisions at root s = 13TeV and constraints on dark matter and other models (vol 78, 789, 2018)
No full textIn this article the author name Luigi Calligaris was incorrectly written as A. Calligaris. The original article has been corrected
Measurement of exclusive Upsilon photoproduction from protons in pPb collisions at root s(NN) = 5.02 TeV (vol 79, 277, 2019)
No full textIn this article the author name Luigi Calligaris was incorrectly written as A. Calligaris. The original article has been corrected
Measurement of the top quark mass with lepton+jets final states using pp collisions at root s = 13TeV (vol 78, 891, 2018)
No full textIn this article the author name Luigi Calligaris was incorrectly written as A. Calligaris. The original article has been corrected
- …
